6533b82cfe1ef96bd128ff4f

RESEARCH PRODUCT

Cancer Signaling Transcriptome Is Upregulated in Type 2 Diabetes Mellitus

Albert SanllorenteOlga CastañerEnrique Almanza-aguileraEnrique Almanza-aguileraÁLvaro HernáezJulieta ValussiIsaac SubiranaOlga PortolésOlga PortolésCristina RazquinCristina RazquinEmilio RosEmilio RosGemma BlanchartMontserrat FitóSilvia CanudasOscar ColtellRamon EstruchRamon EstruchDolores CorellaDolores CorellaLara Nonell

subject

endocrine system diseasesMicroarrayIntegrinT cellslcsh:Medicine030209 endocrinology & metabolismInflammationPeripheral blood mononuclear cellArticleDiabetis no-insulinodependentTranscriptome03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDownregulation and upregulationmedicinecancerNon-insulin-dependent diabetesCàncer030304 developmental biologyCancer0303 health sciencesbiologybusiness.industrylcsh:Rnutritional and metabolic diseasesGeneral Medicinesignaling pathwayschemistryCèl·lules TGuanosine diphosphateCancer researchbiology.proteintype 2 diabetesmedicine.symptomSignal transductionbusinesstranscriptomemicroarray

description

We aimed to explore the differences in the whole transcriptome of peripheral blood mononuclear cells between elderly individuals with and without type 2 diabetes (T2D). We conducted a microarray-based transcriptome analysis of 19 individuals with T2D and 15 without. Differentially expressed genes according to linear models were submitted to the Ingenuity Pathway Analysis system to conduct a functional enrichment analysis. We established that diseases, biological functions, and canonical signaling pathways were significantly associated with T2D patients when their logarithms of Benjamini&ndash

yearjournalcountryeditionlanguage
2020-12-29
10.3390/jcm10010085http://hdl.handle.net/2445/176069